Skip to main content
Eric Jou
Fellow

Dr Eric Jou

Bye Fellow

Social media
LinkedIn

Biography

Eric is an NIHR Academic Clinical Fellow in Medical Oncology at the Cambridge Deanery, and currently conducts research at CRUK Cambridge Institute and University of Cambridge Department of Oncology, alongside clinical work at Cambridge University Hospitals and Royal Papworth Hospital NHS Foundation Trusts. He has research interests in tumour immunology, cancer immunotherapy and bone research, with peer-reviewed publications in renowned journals including Science and Science Immunology.

Eric graduated with Distinction in Medicine (MB BChir) from the University of Cambridge School of Clinical Medicine, and was Exhibitioner and Foundation Scholar at Queens’ College, University of Cambridge. He completed his PhD in cancer immunology at the MRC Laboratory of Molecular Biology, as part of the Cambridge MB/PhD programme as Sir Peter Lachmann Fellow. He was competitively appointed onto the Academic Foundation Programme at Oxford where he conducted oncology clinical trials and laboratory research at the Early Phase Clinical Trials Unit, Department of Oncology and MRC Weatherall Institute of Molecular Medicine, and was elected Junior Research Fellow at Kellogg College, University of Oxford.

Eric is an avid educator, and was previously Supervisor in Medicine at five University of Cambridge Colleges teaching second year medical and natural sciences students the Pathology course, and currently mentors medical students in clinical and research settings. 

Degrees

  • PhD in Cancer Immunology, University of Cambridge
  • MB BChir (Dist), Medicine, University of Cambridge
  • MA (Cantab), University of Cambridge
  • BA (Hons) in Preclinical Medical Studies, University of Cambridge

Research Interests

  • Tumour Immunology
  • Cancer immunotherapy
  • Cancer patient stratification
  • Liquid biopsy
  • Bone research 

Honours

  • AFHEA, Associate Fellow of AdvanceHE
  • MAcadMEd, Member of the Academy of Medical Educators

Major Awards and Prizes

  • NIHR Academic Clinical Fellowship in Medical Oncology, Cambridge East of England Deanery – 2025
  • Sri Iyer Overall Most Promising Trainee Award, Frimley Health NHS Foundation Trust, Oxford Thames Valley Deanery – 2024
  • Foundation Trainee Educator Medical Educational Excellence Award, Frimley Health NHS Foundation Trust, Oxford Thames Valley Deanery – 2024
  • Oxford NHS Specialised Academic Foundation Programme, Oxford Thames Valley Deanery – 2023
  • Fellow, Junior Research Fellow, Kellogg College, University of Oxford – 2023
  • Distinction in Medicine and Top Decile, School of Clinical Medicine, University of Cambridge – 2023
  • Foundation Scholar, Queens’ College, University of Cambridge – 2016
  • College Exhibitioner, Queens’ College, University of Cambridge – 2015 

Authored work

  • Selected publications:

     

    1. Zameer MZ*, Jou E*, Middleton M. The role of circulating tumor DNA in melanomas of the uveal tract. Front Immunol. 2024 Dec 4;15:1509968. doi: 10.3389/fimmu.2024.1509968. PMID: 39697328; PMCID: PMC11652350.
    2. Szeto ACH, Clark PA, Ferreira ACF, Heycock M, Griffiths EL, Jou E, Mannion J, Luan SL, Storrar S, Knolle MD, Kozik P, Jolin HE, Fallon PG, McKenzie ANJ. Mef2d potentiates type-2 immune responses and allergic lung inflammation. Science. 2024 Jun 28;384(6703):eadl0370. doi: 10.1126/science.adl0370. Epub 2024 Jun 28. PMID: 38935708.
    3. Verner JM, Arbuthnott HF, Ramachandran R, Bharadwaj M, Chaudhury N, Jou E. Emerging Roles of ILC1s in Tumour Pathogenesis and Cancer Immunotherapy. Explor Target Antitumor Ther. 2024;5:296–315. doi: 10.37349/etat.2023.00219. Epub 2024 April 23. PMID: 38745765.
    4. O’Connor O, Patel R, Thahir A, Ho JS, Jou E. The use of Three-Dimensional Printing in Orthopaedics: a Systematic Review and Meta-analysis. Arch Bone Jt Surg. 2024;12(7):441-56. doi: 10.22038/abjs.2024.74117.3465. PMID: 39070875.
    5. Jou E*, Chaudhury N*, Nasim F. Novel Therapeutic Strategies Targeting Myeloid-derived Suppressor Cell Immunosuppressive Mechanisms for Cancer Treatment. Explor Target Antitumor Ther. 2024;5(1):187-207. doi: 10.37349/etat.2024.00212. Epub 2024 Feb 28. PMID: 38464388; PMCID: PMC10918238.
    6. Jou E, Rodriguez-Rodriguez N, Ferreira AF, Jolin HE, Clark PA, Sawmynaden K, Ko M, Murphy JE, Mannion J, Ward C, Matthews DJ, Buczacki SJA, McKenzie ANJ. An Innate IL-25-ILC2-MDSC Axis Creates a Cancer-permissive Microenvironment for Apc mutation-driven Intestinal Tumorigenesis. Sci Immunol. 2022 Jun 3;7(72):eabn0175. doi: 10.1126/sciimmunol.abn0175. Epub 2022 Jun 3. PMID: 35658010; PMCID: PMC7612821.
    7. Jou E. Type 1 and Type 2 Cytokine-mediated Immune Orchestration in the Tumour Microenvironment and Their Therapeutic Potential. Explor Target Antitumor Ther. 2023;4(3):474-497. doi: 10.37349/etat.2023.00146. Epub 2023 Jun 30. PMID: 37455828; PMCID: PMC10345208.
    8. Jou E, Rodriguez-Rodriguez N, McKenzie ANJ. Emerging Roles for IL-25 and IL-33 in Colorectal Cancer Tumorigenesis. Front Immunol. 2022 Oct 3;13:981479. doi: 10.3389/fimmu.2022.981479. PMID: 36263033; PMCID: PMC9573978.
    9. Rana BMJ, Jou E, Barlow JL, Rodriguez-Rodriguez N, Walker JA, Knox C, Jolin HE, Hardman CS, Sivasubramaniam M, Szeto A, Cohen ES, Scott IC, Sleeman MA, Chidomere CI, Cruz Migoni S, Caamano J, Jorgensen HF, Carobbio S, Vidal-Puig A, McKenzie ANJ. A Stromal Cell Niche Sustains ILC2-mediated Type-2 Conditioning in Adipose Tissue. J Exp Med. 2019 Sep 2;216(9):1999-2009. doi: 10.1084/jem.20190689. Epub 2019 Jun 27. PMID: 31248899; PMCID: PMC6719433.
    10. Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Peres RMR, Punturi N, Schmidt C, Bartram A, Jou E, Devarakonda V, Holloway KR, Lai WV, Hampton O, Rogers A, Tobias E, Parikh PA, Davies SR, Li S, Ma CX, Suman VJ, Hunt KK, Watson MA, Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ. Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep. 2018 Aug 7;24(6):1434-1444.e7. doi: 10.1016/j.celrep.2018.07.009. PMID: 30089255; PMCID: PMC6171747.

     

    Book chapters:

    1. Jou E. Clinical and Basic Science Aspects of Innate Lymphoid Cells as Novel Immunotherapeutic Targets in Cancer Treatment. In Teplow D. (Eds), Progress in Molecular Biology and Translational Science. Elsevier. 2024 April. doi: 10.1016/bs.pmbts.2024.03.036.
    2. Jatoi I, Shaaban AM, Jou E, Benson JR. The Biology and Management of Ductal Carcinoma in Situ of the Breast. Curr Probl Surg. 2023 Aug;60(8):101361. doi: 10.1016/j.cpsurg.2023.101361. Epub 2023 Jul 6. PMID: 37596033.
    3. Benson JR, Jou E, Jatoi I. Over-diagnosis and Breast Cancer Screening. In Toi M. (Eds.), Screening and Risk Reduction Strategies for Breast Cancer. Springer Nature. 2022 Dec. doi: 10.1007/978-981-19-7630-8_4.

     

Subject
Medicine